Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Severe myoclonic epilepsy in infancy (Dravet syndrome) Clinical criteria: Patient must have (as an initiating patient)/have had (as a continuing patient), generalised tonic-clonic seizures or generalised clonic seizures that are not adequately controlled with at least two other antiseizure medications, AND The treatment must be as adjunctive therapy to at least two other antiseizure medications. Treatment criteria: Must be treated by a neurologist if treatment is being initiated; OR Must be treated by a neurologist if treatment is being continued or re-initiated; OR Must be treated by a paediatrician in consultation with a neurologist if treatment is being continued; OR Must be treated by a general practitioner in consultation with a neurologist if treatment is being continued.
“The mechanism of antiepileptic activity of stiripentol is based on the potentiation of the GABAergic transmissions in the CNS.”
“The half-life of elimination was in the range of 4.5 hours to 13 hours, increasing with dose.”
“At therapeutic concentrations, stiripentol significantly inhibits several CYP450 isoenzymes: for example, CYP2C19, CYP1A2, CYP2C8, CYP2D6, CYP2C9 and CYP3A4.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.